Contribution: Industrial Research Assistance Program – Contributions to Firms
Medicago Inc.
$1,915,000.00
Development of a plant-based candidate combination vaccine for SARS-CoV-2 and seasonal influenza
FY 2018-19 · 2019-01-01
Summary
Development of a plant-derived candidate universal influenza vaccine ready for clinical development
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Quebec|Québec, Quebec, Canada
Recipient Type
For-profit organization
Business Number
872308499
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-01-01 | 2018-19 | $2,515,000.00 |
| 2 | 2019-01-01 | 2018-19 | $2,515,000.00 |
| 6 | 2019-01-01 | 2018-19 | $1,915,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days. The total amended value is -600,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 90 jours. La valeur totale des modifications est de - 600 000 dollars.
Agreement End Date
2023-03-31
Agreement Number
920200
Agreement Start Date
2019-01-01
Agreement Title
Development of a plant-based candidate combination vaccine for SARS-CoV-2 and seasonal influenza
Agreement Title (French)
Développement d'un candidat vaccin combiné à base de plantes pour le SRAS-CoV-2 et la grippe saisonnière
Agreement Type
Contribution
Agreement Value
$1,915,000.00
Amendment Date
2022-06-01
Amendment Number
6
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Development of a plant-derived candidate universal influenza vaccine ready for clinical development
Description (French)
Développement d'un candidat vaccin universel contre la grippe, dérivé de plantes, prêt pour le développement clinique.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Louis-Hébert
Federal Riding (French)
Louis-Hébert
Federal Riding Number
24044
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
872308499
Recipient City
Quebec|Québec
Recipient Country
CA
Recipient Legal Name
Medicago Inc.
Recipient Postal Code
G1V 3V9
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2018-2019-Q4-920200
